Analyst Serge Belanger from Needham maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) and increased the price target to $32.00 from $30.00.
Serge Belanger has given his Buy rating due to a combination of factors including Pacira Pharmaceuticals’ strategic initiatives and financial outlook. The company has outlined its 2025 guidance with projected revenues between $725 million and $765 million, aligning with market expectations. This growth is anticipated to be driven by increased volumes of Exparel, particularly benefiting from the NOPAIN initiative in the latter half of 2025.
Additionally, Pacira’s acquisition of the remaining stake in GQ Bio enhances its pipeline and aligns with its 5×30 strategy, which focuses on strategic investments. This acquisition not only eliminates future milestone payments but also strengthens the company’s position in the market. These factors collectively support the Buy rating as they indicate a positive growth trajectory and strategic alignment for Pacira Pharmaceuticals.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $48.00 price target.